title: Stroke and Bleeding Risks in NOAC- and Warfarin-Treated Patients With Hypertrophic Cardiomyopathy and Atrial Fibrillation.
authors.forename: Peter A
authors.initials: PA
authors.lastname: Noseworthy
authors.forename: Xiaoxi
authors.initials: X
authors.lastname: Yao
authors.forename: Nilay D
authors.initials: ND
authors.lastname: Shah
authors.forename: Bernard J
authors.initials: BJ
authors.lastname: Gersh
mesh_terms: D000368:Aged; D000925:Anticoagulants / Q000008:administration & dosage / Q000009:adverse effects / Q000145:classification; D001281:Atrial Fibrillation / Q000188:drug therapy* / Q000209:etiology; D002312:Cardiomyopathy, Hypertrophic / Q000150:complications / Q000453:epidemiology; D005260:Female; D006470:Hemorrhage / Q000139:chemically induced / Q000453:epidemiology; D006801:Humans; D015994:Incidence; D007345:Insurance Claim Review / Q000706:statistics & numerical data; D008297:Male; D008875:Middle Aged; D020379:Risk Adjustment / Q000379:methods; D020521:Stroke / Q000453:epidemiology / Q000209:etiology / Q000517:prevention & control; D014481:United States / Q000453:epidemiology
chemical_list: D000925:Anticoagulants